Clinical Trial Update: Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia [EARLY_Phase 1]

View source ↗

Summary

An early-phase study of SYNCAR-100 is investigating its use in relapsed/refractory B-cell acute lymphoblastic leukemia. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• SYNCAR-100

Snippet

Sponsor: Zhejiang University | Conditions: B-Cell Acute Lymphoblastic Leukemia | EARLY_Phase 1 | Status: RECRUITING